Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

AI is already accelerating drug discovery and health delivery. It has great potential to accelerate research, workflow and processes, and even reengineer entire healthcare systems. But what challenges must be addressed first? Shahram Ebadollahi and Ann Aerts share the ideas they discussed at the Intelligent Health summit in Basel this week.

Novartis’ Don Ganem tapped as a scientific advisor for the Chan Zuckerberg Biohub